A cleaner pharma giant, with legal baggage
- North American Pharmaceutical is the core, with fiscal 2026 revenue of $336.7 billion.
- Oncology & Multispecialty grew 31% in fiscal 2026, helped by provider solutions and specialty drug sales.
- McKesson plans to separate Medical-Surgical Solutions, with Apollo Funds set to buy about 13% for about $1.25 billion.
- The largest customer made up 24% of consolidated revenue, so one major account can matter a lot.
- Opioid litigation is still a large overhang, with an estimated liability of $5.7 billion at March 31, 2026.
Focus is the bet
McKesson is trying to become a simpler company. Today it is still a huge drug distributor, a specialty care services owner, a prescription technology business, and a medical-supply distributor. The plan is to separate Medical-Surgical Solutions so investors can value the remaining pharma and specialty care business more directly.
The bull case is that this shift is already showing up in the numbers. Oncology & Multispecialty revenue rose 31% in fiscal 2026 to $48.4 billion. That segment includes specialty drug distribution, the U.S. Oncology Network, PRISM Vision, Core Ventures, and related research and technology services.
Apollo Funds agreeing to buy about 13% of Medical-Surgical Solutions for about $1.25 billion gives the separation plan more weight. It also gives investors a rough marker for what part of that business may be worth. If McKesson can finish the split cleanly, the market may pay more attention to the faster-growing oncology and technology pieces.
The bear case is simple too. The biggest segment is still a thin-margin, high-volume drug distribution business. McKesson also has a $5.7 billion estimated opioid-related liability, a large customer that accounts for 24% of revenue, and a separation plan that could cost more, take longer, or fail to deliver the promised benefits.
Scale makes the machine work
McKesson sits between drug makers, pharmacies, hospitals, doctors, patients, and governments. It buys, stores, moves, and helps manage medicines across North America and other markets. This is a scale business, which means size helps lower unit costs and makes the company harder to replace.
Most revenue comes from distributing branded, generic, specialty, and over-the-counter drugs. The dollar amounts are huge, but margins are usually small because McKesson is moving products for others. Profit depends on volume, purchasing terms, service fees, and keeping the network running with few mistakes.
The growth push is in specialty care and prescription technology. Oncology, ophthalmology, medication access tools, price transparency, and patient affordability services can be more attractive than basic drug distribution if they grow without adding too much complexity.
Where it breaks is concentration and trust. If a national retail customer changes terms or leaves, revenue can move quickly. If regulators, courts, or customers lose confidence in how McKesson handles controlled substances, data, or supply chain duties, the costs can last for years.
What McKesson sells
North American drug distribution
This is the largest business. It distributes branded, generic, specialty, and over-the-counter drugs in the U.S. and Canada.
Oncology and specialty provider services
This includes specialty drug distribution, the U.S. Oncology Network, PRISM Vision, Core Ventures, and practice management services. Fiscal 2026 revenue grew 31%.
Prescription Technology Solutions
RxTS connects patients, pharmacies, providers, and biopharma companies. It helps with medication access, affordability, adherence, and price transparency.
Medical-Surgical Solutions
This business distributes medical-surgical supplies to non-acute care settings. McKesson intends to separate it, and Apollo Funds agreed to buy about 13%.
Biopharma services
McKesson provides logistics, access, and other services for drug makers. These services make it more than a basic warehouse and trucking company.
International services
Outside the main U.S. business, McKesson provides drug distribution, specialty pharmacy, and infusion care services. The company has also been simplifying parts of this footprint.
Revenue mix is still pharma-heavy
Segment shares use fiscal 2026 revenue from McKesson's Form 10-K: $336.7 billion for North American Pharmaceutical, $48.4 billion for Oncology & Multispecialty, $5.8 billion for RxTS, and $11.5 billion for Medical-Surgical Solutions. The largest customer represented 24% of consolidated revenue, which is a key concentration caveat.
What could break the thesis
Medical-Surgical separation misses the plan
High impact · Medium oddsMcKesson now has a specific risk factor for the planned Medical-Surgical Solutions separation. The deal may not close on the expected terms or timeline, may have tax costs, and may not create the financial benefits management expects.
Opioid costs stay large
High impact · Medium oddsMcKesson estimated its opioid-related claims liability at $5.7 billion as of March 31, 2026. That is smaller than the $6.9 billion estimate from June 30, 2024, but it remains a major long-term cash claim on the business.
One large customer gains leverage
High impact · Medium oddsThe largest customer accounted for 24% of consolidated revenue. That makes McKesson exposed to contract renewals, pricing pressure, payment delays, or volume shifts from a single account.
Core distribution margin pressure
Medium impact · High oddsNorth American Pharmaceutical produced $336.7 billion of fiscal 2026 revenue, but drug distribution is a low-margin business. If customers demand better pricing or drug mix turns less favorable, revenue can grow while profit grows more slowly.
Oncology acquisitions fail to scale
Medium impact · Medium oddsThe growth case leans on Oncology & Multispecialty, including PRISM Vision and Core Ventures. Fast revenue growth is helpful, but the key question is whether these businesses can keep growing while earning good margins after integration.
In one breath
What does McKesson actually do?
McKesson is a healthcare middleman. It distributes drugs and medical products, helps pharmacies and providers manage prescriptions, and provides services to specialty care practices and drug makers.
Why is McKesson separating Medical-Surgical Solutions?
The goal is to make McKesson more focused on pharmaceuticals, specialty care, and prescription technology. Apollo Funds agreeing to buy about 13% of Medical-Surgical Solutions for about $1.25 billion makes the plan more concrete, but execution risk is now a major issue to watch.
Is McKesson mostly an oncology company now?
No. North American Pharmaceutical is still far larger, with fiscal 2026 revenue of $336.7 billion. Oncology & Multispecialty is the faster-growing piece, with fiscal 2026 revenue of $48.4 billion and 31% growth.
What is the biggest risk for McKesson investors?
There is no single risk. The main ones are the $5.7 billion opioid-related liability, customer concentration, thin margins in drug distribution, and whether the Medical-Surgical separation works as planned.